Production Approval for Capmatinib

Release date: 2024-07-10 14:49:13     Recommended: 553

TABRECTA is suitable for treating adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have mutations that lead to a jump in exon 14 of mesenchymal epithelial transition (MET) according to FDA approved testing. MET gene mutation is one of the rare mutations in lung cancer, including MET14 jump mutation (3%) and MET amplification (1%).